Evidence map›Paper›PMID 42098130›Full record

ReviewNature communications2026

From hype to hope: reanimating phage therapy through evidence-based multidisciplinarity.

Aleksandra Petrović-Fabijan, Stephen T Abedon

Abstract readReview
In one paragraph

Review in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Aleksandra Petrović-Fabijan *Centre for Infectious Diseases and Microbiology, Westmead Institute for Medical Research, Sydney, NSW, Australia. aleksandra.petrovicfabijan@sydney.edu.au.ORCID 0000-0003-3172-2375
Stephen T Abedon *Department of Microbiology, The Ohio State University, Mansfield, OH, USA. abedon.1@osu.edu.

Funding

U.S. Department of Health & Human Services | U.S. Public Health Service (United States Public Health Service) R01AI169865
6 · The paper itself

Abstract

Phage therapy must move beyond anecdote to clinical reproducibility. Despite compelling cases of bacteriophages curing otherwise untreatable infections, inconsistent outcomes and biological complexity continue to limit clinical adoption. Here we identify three foundational pillars-drug delivery, treatment effectiveness, and managing bacterial resistance that must be addressed through interdisciplinary collaboration to transform phage therapy from a niche intervention to a powerful weapon against antimicrobial resistance. The time for rigorous, translational phage science is now.

Indexed as

Bacterial InfectionsBacteriophagesPhage TherapyAnti-Bacterial AgentsBacteriaDrug Resistance, BacterialHumansAnti-Bacterial Agents

Identifiers

PMID42098130
PMCPMC13153206

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.